SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatDate: Tuesday ...

Group 1 - The management team of Perspective Therapeutics is open to questions from the audience, utilizing a QR code for submissions [1] - The focus of Perspective Therapeutics includes key clinical programs that are currently in development [2]

Financial Performance - Grant revenue for Q3 2025 was $209,000, a decrease of 43% compared to $369,000 in Q3 2024[15] - Total operating expenses for Q3 2025 were $28,070,000, up 48% from $19,003,000 in Q3 2024[15] - Net loss from continuing operations for Q3 2025 was $25,969,000, compared to a loss of $15,122,000 in Q3 2024, representing a 72% increase in losses[15] - The company reported a net loss of $65,631,000 for the nine months ended September 30, 2025, compared to a loss of $39,110,000 for the same period in 2024, reflecting a 68% increase in losses[17] - The company experienced a net loss of $25.969 million for the quarter ended September 30, 2025, compared to a net loss of $21.485 million for the previous quarter[30] - Total operating expenses for the nine months ended September 30, 2025, were $74.573 million, up from $47.122 million in 2024[15] Cash and Liquidity - Cash, cash equivalents, and restricted cash at the end of Q3 2025 were $26,762,000, down from $226,443,000 at the end of Q3 2024[17] - As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments of $174.1 million, with a total accumulated deficit of $297.4 million[30] - The company plans to fund its operations into late 2026 with its current cash reserves, but may seek additional capital through various means[31] - The Company has $24.4 million in cash equivalents as of September 30, 2025, down from $59.7 million at the end of 2024[77] - The total cash equivalents and available-for-sale securities as of September 30, 2025, were $171.800 million, compared to $225.056 million as of December 31, 2024[80] Shareholder Activities - The total number of shares outstanding increased from 70,671,464 at December 31, 2024, to 74,337,990 at September 30, 2025, reflecting the issuance of common stock[19] - A 1-for-10 reverse stock split was executed on June 14, 2024, affecting all stockholders uniformly[28] - Share-based compensation expenses were $2.156 million for the quarter ended September 30, 2025[19] - The Company reported a basic and diluted loss per share, calculated by dividing net loss by the weighted average number of shares outstanding, which did not include potentially dilutive common stock equivalents[35] - As of September 30, 2025, there were 10,902,610 total potentially dilutive securities, compared to 7,667,413 as of September 30, 2024, indicating an increase of approximately 42.5%[36] Business Operations - The company has not generated revenue from commercial products and incurs the majority of its operating expenses in the United States[29] - The company has a single operating segment focused on radiopharmaceutical development, with no significant changes in accounting policies reported[29] - The company is focused on obtaining regulatory approvals for its future program candidates, including Fast Track designation for PSV359 from the FDA[8] - The company is leveraging technology to identify and develop future program candidates, aiming to enhance its competitive position in the market[8] Asset Management - As of September 30, 2025, the Company's property and equipment, net, was valued at $64.4 million, an increase from $57.3 million as of December 31, 2024[74] - The Company holds indefinite-lived intangible assets valued at $50.0 million, representing the estimated fair value of its pipeline of acquired radiotherapy program candidates[75] - The Company recognized a total gain from discontinued operations of $514,000 for the nine months ended September 30, 2025, while incurring a loss of $949,000 for the same period in 2024[69] Financing Activities - The Company entered into a 2024 ATM Agreement allowing for the sale of up to $250.0 million of Common Stock, with a commission of up to 3.0% on gross proceeds from each sale[39][40] - The Company raised approximately $10.2 million from the sale of 3,379,377 shares at an average price of $3.02 per share under the 2024 ATM Agreement on February 18, 2025[43] - The gross proceeds from the May 2024 Registered Offering were approximately $80.0 million, before underwriting discounts and commissions[45] - The Company completed a private placement on March 6, 2024, raising approximately $87.4 million from the sale of 9,200,998 shares at $9.50 per share[48] - The Company sold 5,634,235 shares to Lantheus for a total of $50.0 million, representing 19.99% of the outstanding shares as of January 8, 2024[51] Lease and Liability Management - The Company recognized a right-of-use asset and lease liability of approximately $1.1 million upon entering into a lease for lab and office space effective April 1, 2024[91] - The Company recognized a right-of-use asset and lease liability of approximately $0.6 million upon entering a lease for office space in Somerset, NJ, which terminates on November 30, 2028[93] - The Company entered into a lease with Unico Properties LLC for office space in Seattle, WA, recognizing a right-of-use asset and lease liability of approximately $0.8 million, terminating in October 2028[95] - The Company's operating lease expense was $0.3 million for the three months ended September 30, 2024, and $0.8 million for the nine months ended September 30, 2025[96] - The total future operating lease payments as of September 30, 2025, amount to $1.863 million, with a total lease liability of $1.675 million after accounting for imputed interest[97] Regulatory and Compliance - The company anticipates potential impacts from U.S. and international trade policies on costs for supplies and materials used in drug development[8] - The Company has accrued an estimated liability of $0.2 million related to settlement negotiations with stockholder plaintiff firms as of September 30, 2025[84] - The Company reduced its estimated liability for hazardous waste removal by $0.3 million, resulting in an estimated liability of $0.2 million as of September 30, 2025[98]

Core Insights - Perspective Therapeutics, Inc. is advancing its clinical programs in radiopharmaceuticals aimed at cancer treatment, with a focus on neuroendocrine tumors, melanoma, and solid tumors [2][24][25] Clinical Highlights - The company is conducting a multi-center, open-label study of [Pb]VMT-α-NET targeting SSTR2-positive neuroendocrine tumors, with interim data presented at major medical conferences [3][4][7] - Updated interim results show a favorable safety profile for [Pb]VMT-α-NET, with no dose-limiting toxicities reported and 80% of patients remaining progression-free [8][9] - Cohort 3 of the [Pb]VMT-α-NET study opened in June 2025, with patients receiving up to four doses every eight weeks [9][10] Financial Summary - As of September 30, 2025, the company had approximately $174 million in cash and short-term investments, down from $227 million at the end of 2024, which is expected to fund operations into late 2026 [7][16][17] - Research and development expenses increased by approximately 69% year-over-year for Q3 2025, totaling $20.3 million, primarily due to increased clinical activities and personnel costs [20] - The net loss for Q3 2025 was $26 million, or $0.35 per share, compared to a net loss of $15.1 million, or $0.21 per share, for the same period in 2024 [23][30] Operational Developments - The company has transitioned its operations to focus on continuing operations following the divestiture of its brachytherapy segment in April 2024 [18] - The company is also developing complementary imaging diagnostics to enhance treatment personalization and optimize patient outcomes [24] Future Outlook - The company anticipates sharing updates on its clinical-stage medicines throughout 2026, with strong patient recruitment and clinical site engagement [7][11] - Plans are in place to submit data from ongoing studies to medical conferences in the coming year [11][12]

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb for targeted radiation delivery to cancer cells [2][3] Company Overview - The company is pioneering advanced treatments for various cancers and is developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes [2] - The "theranostic" approach enables visualization of specific tumors followed by targeted treatment, potentially improving efficacy and minimizing toxicity [2] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready product candidates for clinical trials and commercial operations [3] Upcoming Events - Members of the senior leadership team will participate in the Truist Securities BioPharma Symposium on November 6, 2025, in New York, NY, for one-on-one meetings with investors [1] - The company will also be featured in a Fireside Chat at the UBS Global Healthcare Conference on November 11, 2025, from 4:15 to 4:50 p.m. ET in Palm Beach, FL [2]

Core Insights - Perspective Therapeutics, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 10, 2025, after market close [1] Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, focusing on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2] - The company is also developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Clinical Programs - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Group 1 - The conference is focused on the updated interim clinical data for VMT-alpha-NET being presented at the European Society of Medical Oncology Congress 2025 (ESMO) [2] - The call includes forward-looking statements that are subject to risks and uncertainties, with details available in the company's SEC filings [2][3]

Summary of Perspective Therapeutics Conference Call Company Overview - **Company**: Perspective Therapeutics (NYSEAM:CATX) - **Event**: Update on VMT AlphaNet clinical data presented at the European Society of Medical Oncology (ESMO) Congress 2025 Key Industry Insights - **Focus**: Development of next-generation targeted therapies for neuroendocrine tumors (NETs) - **Clinical Pipeline**: Active clinical and preclinical pipelines with multiple readouts expected through mid-2026 and beyond [6][39] Core Data and Findings - **VMT AlphaNet Program**: - Completed recruitment for the second dose cohort at 5 millicuries and the DLT cohort at 6 millicuries [7] - Melanoma program enrolling at 3 millicuries in both monotherapy and combination therapies [7] - FAP program now enrolling at 5 millicuries, escalated from 2.5 millicuries [7] - **Interim Data**: - Encouraging interim readout with an overall response (OR) rate of 44% and a median follow-up of 41 weeks for patients intended for registrational trials [8][15] - Patients continue to achieve late objective responses as the trial progresses, which is typical for this tumor type [10] - **Safety Profile**: - Treatment-emergent adverse events are mostly mild, with common events being fatigue and alopecia [22] - No dose-limiting toxicities or serious renal complications reported [34] - Creatinine levels remained stable, with only mild increases observed in a few patients [24] Important Considerations - **Patient Selection**: - Focus on "LUTIVAIR naive" patients who have not received prior radiopharmaceutical therapy [12] - Two analyses planned: one for all patients with at least one tumor expressing SSTR2 and another for patients where all tumors express SSTR2 [13] - **Comparative Analysis**: - The response rate of 44% is higher than the published data with Lutathera from the NETTER-one trial [34] - The study design allows for a broader patient eligibility, which may affect the response rates [56] - **Future Directions**: - Plans to accelerate towards pivotal studies based on clinical interest and demand [72] - Continuous follow-up and data collection to refine understanding of response kinetics and safety [39][60] Additional Insights - **Response Kinetics**: - Delayed responses are common in slower proliferating tumors, with some patients showing significant tumor shrinkage after extended treatment periods [61][110] - The importance of long-term follow-up to assess gradual tumor responses [31] - **Differentiation from Competitors**: - Perspective Therapeutics' product shows a favorable safety profile compared to competitors, with no reports of dysphagia, which is a significant concern with other treatments [80][81] - **Clinical Relevance**: - The data presented indicates a potentially meaningful tool for clinicians treating patients with neuroendocrine tumors, emphasizing the importance of quality of life and safety in long-term treatment [118] This summary encapsulates the key points from the conference call, highlighting the company's focus on innovative therapies, promising clinical data, and the importance of patient safety and response evaluation in the treatment of neuroendocrine tumors.

Legal Disclaimers Investor Call ESMO 2025 Presentation October 20, 2025 NYSE AMERICAN: CATX Forward-looking statements contained in this presentation are made as of this date. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward- looking statements whether as a result of new information, future events or otherwise. Innovative Platform Technology Robust Manufacturing Infrastructure This presentation contains forward-looking statements within the meani ...

[Filing Information](index=1&type=section&id=Filing%20Information) Details registrant identification, principal offices, and registered securities for Perspective Therapeutics, Inc [Registrant Information](index=1&type=section&id=Registrant%20Information) Provides core identification details for Perspective Therapeutics, Inc., including incorporation, principal executive offices, and registered securities - **Registrant**: Perspective Therapeutics, Inc., incorporated in Delaware[2](index=2&type=chunk) - Principal Executive Offices: 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121, Telephone: (206) 676-0900[2](index=2&type=chunk) Registered Securities | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common Stock, $0.001 par value | CATX | NYSE American LLC | [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Perspective Therapeutics, Inc. announced updated interim clinical trial results and preliminary estimated financial information as of September 30, 2025, noting these figures are unaudited and subject to change - On October 20, 2025, the Company announced updated interim results from its Phase 1/2a clinical trial of **[212Pb]VMT-α-NET** for neuroendocrine tumors[6](index=6&type=chunk) - The Press Release and Presentation include estimated **cash, cash equivalents, and short-term investments** as of September 30, 2025[6](index=6&type=chunk) - All estimated and projected financial information is **preliminary, unaudited**, and not reviewed by the independent registered public accounting firm[6](index=6&type=chunk)[7](index=7&type=chunk) [Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%208.01%20Other%20Events%20and%20Item%209.01%20Financial%20Statements%20and%20Exhibits) Details the filing of a Press Release and Presentation as exhibits to the 8-K report, providing further clinical and business updates - On October 20, 2025, the Company issued a Press Release and Presentation, both filed as exhibits to this 8-K report[8](index=8&type=chunk) Filed Exhibits | Exhibit No. | Description | | :------------ | :-------------------------------------------------- | | 99.1 | Press Release dated October 20, 2025 | | 99.2 | Presentation | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signatures](index=4&type=section&id=SIGNATURES) The report was officially signed on October 20, 2025, by Johan (Thijs) Spoor, CEO of Perspective Therapeutics, Inc., affirming compliance - The report was signed by **Johan (Thijs) Spoor**, Chief Executive Officer of Perspective Therapeutics, Inc., on October 20, 2025[14](index=14&type=chunk)